Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Open-Labeled, Multicenter Phase II Study of Bortezomib for Maintenance Therapy in Patients with High Risk Diffuse Large B Cell Lymphoma (DLBCL): Borma Trial from Consortium for Improving Survival of Lymphoma (CISL)

Jae-Cheol Jo, MD, Ho Sup Lee, MD, Cheolwon Suh, Hye Jin Kang, MD PhD, Won Seog Kim, MD PhD, HyeonSeok Eom, MD PhD, Inho Kim, MD PhD, Ho-Jin Shin, MD PhD, Yong Park, Won Sik Lee, MD PhD, Young Rok Do, PhDMD, Lee Gyeong-Won, Sung Yong Oh, Sung-Nam Lim, MD, Seong Yoon Lee, MD

Blood (2019) 134 (Supplement_1): 2884.

https://doi.org/10.1182/blood-2019-132192

Published: 2019

Journal Articles

Prognostic Significance of Interim PET/CT Assessment for the Treatment of Advanced Stage of Marginal Zone Lymphoma in the Post Immunochemotherapy Era

Ga-Young Song, Seok Jin Kim, MD PhD, Sang Eun Yoon, Jin Seok Kim, MD PhD, Ho-Young Yhim, MD PhD, Youngil Koh, MD PhD, Sung Yong Oh, MD PhD, Ho Sup Lee, MD PhD, Ho-Jin Shin, MD PhD, Young Rok Do, MD PhD, Won Sik Lee, MD PhD, Lee Gyeong-Won, Dae Sik Kim, Yong Park, Deok-Hwan Yang, MD PhD

Blood (2019) 134 (Supplement_1): 4002.

https://doi.org/10.1182/blood-2019-126574

Published: 2019

Journal Articles

Pomalidomide, Cyclophosphamide, and Dexamethasone for Elderly, Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma Who Had Failed Treatment with Lenalidomide and Bortezomib: A Study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)

Ho Sup Lee, MD PhD, Chang-Ki Min, MD PhD, Kihyun Kim, MD, Seok Jin Kim, MD PhD, Je-Jung Lee, MD PhD, Inho Kim, MD PhD, Sung-Soo Yoon, MD PhD, Jin Seok Kim, MD PhD, Hyeon-Seok Eom, MD PhD, Dok Hyun Yoon, MD PhD, Cheolwon Suh, Ho-Jin Shin, MD PhD, Yeung-Chul Mun, MD, Min Kyoung Kim, MD PhD, Sung-Nam Lim, MD, Chul Won Choi, Hye Jin Kang, MD PhD

Blood (2019) 134 (Supplement_1): 3114.

https://doi.org/10.1182/blood-2019-122404

Published: 2019

Journal Articles

Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of the Castor, Pollux, and MMY1001 Studies

Blood (2018) 132 (Supplement 1): 3288.

https://doi.org/10.1182/blood-2018-99-112669

Published: 2018

Journal Articles

Benefit of Two Additional Cycles of Bortezomib/Thalidomide/Dexamethasone (VTD) Induction Therapy Compared to Four Cycles of VTD for Newly Diagnosed Multiple Myeloma

Yoojin Lee, MD PhD, Kihyun Kim, MD PhD, Sang Kyun Sohn, MDPhD, Dongwon Back, MD, Joon Ho Moon, MD, Je-Jung Lee, MD PhD, Jae-Cheol Jo, MD, Won-Sik Lee, MD, Ho-Jin Shin, MD PhD, Sung-Hyun Kim, MD PhD, Ji Hyun Lee, MD PhD, Sung Hwa Bae, MD, Min Kyoung Kim, MD PhD, Ho Sup Lee, MD, Chang-Ki Min, MD PhD

Blood (2018) 132 (Supplement 1): 3252.

https://doi.org/10.1182/blood-2018-99-113229

Published: 2018

Journal Articles

The Survival of Transplant Ineligible Multiple Myeloma Patients Treated with Bortezomib-Based Chemotherapy Is Affected By the Patient Fitness

Ji Hyun Lee, MD PhD, Sung-Hyun Kim, MD PhD, Seok Jae Huh, Jae-Cheol Jo, MD PhD, Ho-Jin Shin, MD PhD, Won-Sik Lee, Yoojin Lee, MD PhD, Ho Sup Lee, MD

Blood (2018) 132 (Supplement 1): 3307.

https://doi.org/10.1182/blood-2018-99-119473

Published: 2018

Journal Articles

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up

Blood (2018) 132 (Supplement 1): 1733.

https://doi.org/10.1182/blood-2018-99-110568

Published: 2018

Journal Articles

Comparison of Prognostic Stratification between IPI, PIT, and NCCN-IPI in the Treatment of Nodal Peripheral T-Cell Lymphomas

Ho-Young Yhim, MD PhD, Yong Park, MD, Joon Ho Moon, MD, Ho-Jin Shin, MD PhD, Yoon Seok Choi, MD, Min Kyoung Kim, MD PhD, Dae Sik Kim, MD PhD, Ji Hyun Lee, MD PhD, Won Sik Lee, MD PhD, Young Rok Do, PhDMD, Jun Soo Ham, MD, Seok Jin Kim, MD PhD, Won Seog Kim, MD PhD, Deok-Hwan Yang, MD, Jae-Yong Kwak, MD PhD

Blood (2018) 132 (Supplement 1): 1657.

https://doi.org/10.1182/blood-2018-99-115620

Published: 2018

Journal Articles

The Prognostic Implication of Inflammatory Factor-Based Scoring System in Diffuse Large B-Cell Lymphoma Patients in the Rituximab Era

Ji Hyun Lee, MD PhD, Sung Yong Oh, Jae-Cheol Jo, MD PhD, Yunsuk Choi, MD, Ho-Jin Shin, MD PhD, Won-Sik Lee, MD, Kwon Kyung A, Yoojin Lee, MD, Ho Sup Lee, MD

Blood (2017) 130 (Supplement 1): 4142.

https://doi.org/10.1182/blood.V130.Suppl_1.4142.4142

Published: 2017

Journal Articles

Blinatumomab Treatment in Korean Adult Patients with Relapse/Refractory Acute Lymphoblastic Leukemia

Sung-Hoon Jung, MD, Deok-Hwan Yang, MD PhD, Jae-Ho Yoon, MD PhD, Seok Lee, MD PhD, Dae Sik Kim, MD PhD, Se Ryun Lee, MD PhD, Sung-Hyun Kim, MD PhD, Ji Hyun Lee, MD PhD, Soo-Mee Bang, MD PhD, Youngil Koh, MD, Ho-Young Yhim, MD, Sang Kyun Sohn, MDPhD, Ik-Chan Song, MD, Hong-ghi Lee, MD PhD, June-Won Cheong, MDPhD, Yunsuk Choi, MD, Ho-Jin Shin, MD PhD

Blood (2017) 130 (Supplement 1): 5004.

https://doi.org/10.1182/blood.V130.Suppl_1.5004.5004

Published: 2017

Journal Articles

Neutropenia Following Intravenous Immunoglobulin Therapy in Adult Patients with Immune Thrombocytopenic Purpura

Sang Bo Oh, MD, Ho-Jin Shin, MD PhD

Blood (2017) 130 (Supplement 1): 3631.

https://doi.org/10.1182/blood.V130.Suppl_1.3631.3631

Published: 2017

Journal Articles

Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up

Blood (2017) 130 (Supplement 1): 317.

https://doi.org/10.1182/blood.V130.Suppl_1.317.317

Published: 2017

Journal Articles

Phase II Trial of R-CVP Followed By Rituximab Maintenance Therapy for Patients with Advanced Stage Marginal Zone Lymphoma- Consortium for Improving Survival of Lymphoma (CISL) Study

Blood (2016) 128 (22): 1811.

https://doi.org/10.1182/blood.V128.22.1811.1811

Published: 2016

Journal Articles

The Efficacy of JAK2 Inhibitor in Heavily Pretreated Classical Hodgkin Lymphoma: A Prospective Pilot Study of Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma

Seok Jin Kim, MD PhD, Hye Jin Kang, MD PhD, Shin Dong-Yeop, MD PhD, Ho Sup Lee, Sung Yong Oh, MD, Ho-Jin Shin, MD PhD, Dok Hyun Yoon, Jung Yong Hong, MD, Jee Hyun Kong, Kana Sakamoto, Young Hyeh Ko, MD, Kengo Takeuchi, MD PhD, Cheolwon Suh, Won Seog Kim

Blood (2016) 128 (22): 1820.

https://doi.org/10.1182/blood.V128.22.1820.1820

Published: 2016

Journal Articles

The Impact of Antithymocyte Globulin (ATG) Dose in Allogeneic Hematopoietic Stem Cell Transplantation with HLA Mismatched Donors

Yunsuk Choi, MD PhD, Ho Sup Lee, MD PhD, Je-Hwan Lee, MD, Joon Ho Moon, MD, PhD, Ho-Jin Shin, MD PhD, Won Sik Lee, MD PhD

Blood (2016) 128 (22): 3393.

https://doi.org/10.1182/blood.V128.22.3393.3393

Published: 2016

Journal Articles

Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor

Asher A. Chanan-Khan, MD, Suzanne Lentzsch, MD PhD, Hang Quach, MBBS (Hons), FRACP, FRCPA, MD, Noemi Horvath, MB, ChB, FRACP, FRCPA, Marcelo Capra, MD PhD, Roberto Ovilla, MD PhD, Jae-Cheol Jo, MD PhD, Ho-Jin Shin, MD PhD, Ming Qi, William Deraedt, Jordan Schecter, Himal Amin, Xiang Qin, Tineke Casneuf, Christopher Chiu, A. Kate Sasser, Pieter Sonneveld, MD PhD

Blood (2016) 128 (22): 3313.

https://doi.org/10.1182/blood.V128.22.3313.3313

Published: 2016

Journal Articles

Randomized Phase II Multi-Center Trial of Busulfan, Etoposide, and Cyclophosphamide Versus Busulfan, Etoposide, and Melphalan As Conditioning Therapy for Autologous Transplantation in Patients with Non-Hodgkin's Lymphoma: A Multicenter Study from Consortium for Improving Survival of Lymphoma (CISL)

Kyoung Ha Kim, Lee Jae Hoon, Mark Lee, Kim Hoon-Gu, Young Rok Do, Yong Park, MD PhD, Sung Yong Oh, MD, Ho-Jin Shin, MD PhD, Won Seog Kim, Sung-Kyu Park, MD, Jong-Ho Won, Jee Hyun Kong, Moo-Rim Park, MD, Je-Jung Lee, Jae-Yong Kwak, Hye Jin Kang, MD PhD, Yeung-Chul Mun

Blood (2016) 128 (22): 3466.

https://doi.org/10.1182/blood.V128.22.3466.3466

Published: 2016

Journal Articles

Prospective, Non-Randomized, Open-Label, Single-Arm, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Immunoglobulin 10% Formulation in Patients with Immune Thrombocytopenia (ITP)

Soo-Mee Bang, Yeung-Chul Mun, Ho-Jin Shin, MD PhD, Chul Won Jung, Sung Hwa Bae, Sang Kyun Sohn, Kyoung Ha Kim, Hawk Kim, Ho-Young Yhim, MD PhD, Junshik Hong, Hye Joo Kim, Jae-hoon Lee, Doyeun Oh

Blood (2016) 128 (22): 4938.

https://doi.org/10.1182/blood.V128.22.4938.4938

Published: 2016

Journal Articles

The Outcomes of Korean Patients with Primary Plasma Cell Leukemia: Analysis of Korean Multiple Myeloma Working Party (KMM160)

Sung-Hoon Jung, Je-Jung Lee, Kihyun Kim, MD PhD, Dok Hyun Yoon, Chang-Ki Min, Sang Kyun Sohn, MD, PhD, Chul Won Choi, Ho Sup Lee, Hyo Jung Kim, Ho-Jin Shin, MD PhD, Soo-Mee Bang, Sung-Soo Yoon, MD PhD, Seong Kyu Park, Ho-Young Yhim, Min Kyoung Kim, MD, Jae-Cheol Jo, MD PhD, Yeung-Chul Mun, Jae-Hoon Lee, Jin Seok Kim, MD PhD

Blood (2016) 128 (22): 4445.

https://doi.org/10.1182/blood.V128.22.4445.4445

Published: 2016

Journal Articles

Clinical Usefulness of Inflammatory Factors Based Modified International Prognostic Index in Diffuse Large B Cell Lymphoma Treated with Rituximab Combined Chemotherapy

Cheolsu Kim, MD, Ho Sup Lee, MD PhD, Jae-Cheol Jo, MD PhD, Ho-Jin Shin, MD PhD, Sung Yong Oh, MD, Won Sik Lee, MD, Jee-yeong Jeong, PhD

Blood (2016) 128 (22): 4220.

https://doi.org/10.1182/blood.V128.22.4220.4220

Published: 2016

NARROW

Open-Labeled, Multicenter Phase II Study of Bortezomib for Maintenance Therapy in Patients with High Risk Diffuse Large B Cell Lymphoma (DLBCL): Borma Trial from Consortium for Improving Survival of Lymphoma (CISL)

Prognostic Significance of Interim PET/CT Assessment for the Treatment of Advanced Stage of Marginal Zone Lymphoma in the Post Immunochemotherapy Era

Pomalidomide, Cyclophosphamide, and Dexamethasone for Elderly, Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma Who Had Failed Treatment with Lenalidomide and Bortezomib: A Study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)

Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of the Castor, Pollux, and MMY1001 Studies

Benefit of Two Additional Cycles of Bortezomib/Thalidomide/Dexamethasone (VTD) Induction Therapy Compared to Four Cycles of VTD for Newly Diagnosed Multiple Myeloma

The Survival of Transplant Ineligible Multiple Myeloma Patients Treated with Bortezomib-Based Chemotherapy Is Affected By the Patient Fitness

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up

Comparison of Prognostic Stratification between IPI, PIT, and NCCN-IPI in the Treatment of Nodal Peripheral T-Cell Lymphomas

The Prognostic Implication of Inflammatory Factor-Based Scoring System in Diffuse Large B-Cell Lymphoma Patients in the Rituximab Era

Blinatumomab Treatment in Korean Adult Patients with Relapse/Refractory Acute Lymphoblastic Leukemia

Neutropenia Following Intravenous Immunoglobulin Therapy in Adult Patients with Immune Thrombocytopenic Purpura

Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up

Phase II Trial of R-CVP Followed By Rituximab Maintenance Therapy for Patients with Advanced Stage Marginal Zone Lymphoma- Consortium for Improving Survival of Lymphoma (CISL) Study

The Efficacy of JAK2 Inhibitor in Heavily Pretreated Classical Hodgkin Lymphoma: A Prospective Pilot Study of Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma

The Impact of Antithymocyte Globulin (ATG) Dose in Allogeneic Hematopoietic Stem Cell Transplantation with HLA Mismatched Donors

Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor

Randomized Phase II Multi-Center Trial of Busulfan, Etoposide, and Cyclophosphamide Versus Busulfan, Etoposide, and Melphalan As Conditioning Therapy for Autologous Transplantation in Patients with Non-Hodgkin's Lymphoma: A Multicenter Study from Consortium for Improving Survival of Lymphoma (CISL)

Prospective, Non-Randomized, Open-Label, Single-Arm, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Immunoglobulin 10% Formulation in Patients with Immune Thrombocytopenia (ITP)

The Outcomes of Korean Patients with Primary Plasma Cell Leukemia: Analysis of Korean Multiple Myeloma Working Party (KMM160)

Clinical Usefulness of Inflammatory Factors Based Modified International Prognostic Index in Diffuse Large B Cell Lymphoma Treated with Rituximab Combined Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only